Disintegration, In vitro Dissolution, and Drug Release Kinetics Profiles of κ-Carrageenan-based Nutraceutical Hard-shell Capsules Containing Salicylamide

被引:9
|
作者
Pudjiastuti, Pratiwi [1 ]
Wafiroh, Siti [1 ]
Hendradi, Esti [2 ]
Darmokoesoemo, Handoko [1 ]
Harsini, Muji [1 ]
Fauzi, M. Al Rizqi Dharma [1 ]
Nahar, Lutfun [3 ]
Sarker, Satyajit D. [3 ]
机构
[1] Univ Airlangga, Fac Sci & Technol, Dept Chem, Surabaya 60115, Indonesia
[2] Univ Airlangga, Fac Pharm, Dept Pharmaceut, Surabaya 60115, Indonesia
[3] Liverpool John Moores Univ, Ctr Nat Prod Discovery, Sch Pharm & Biomol Sci, James Parsons Bldg,Byrom St, Liverpool L3 3AF, Merseyside, England
来源
OPEN CHEMISTRY | 2020年 / 18卷 / 01期
关键词
Dissolution; Drug release kinetics; Salicylamide; k-Carrageenan; Capsule;
D O I
10.1515/chem-2020-0028
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The release of drugs from solid drug delivery materials has been studied intently in recent years. Quantitative analyses achieved from in vitro dissolution becomes easier if a zero-order mathematical model is used. Non-gelatin nutraceutical hard-shell capsules of zero size (approximately 0.7-0.8 cm) were produced from carrageenan-based natural polymers, namely carrageenan-alginate (CA) and carrageenan-starch (CS). Disintegration, dissolution and zero-order drug release kinetics of hard-shell capsules containing 100 mg of salicylamide were studied. The disintegration time of CA and CS were observed to be less than 30 min for both CA and CS. In vitro dissolution profile showed that the percentage dissolution of CA capsules was better at pH 4.5, while that of CS was poor at pH 1.2, 4.5 and 6.8. Determination of drug release kinetics profiles of carrageenan-based hardshell capsules utilized the Noyes-Whitney and Peppas-Sahlin modification rules for zero-order. The drug release from carrageenan-based capsules followed zero-order kinetics, especially at pH 6.8, and was compared to the Higuchi model. Salicylamide in CA hard-shell capsules at a pH 6.8 had a release rate constant (k(H)) of 2.91 %(ppm/ppm) min(-1/2), while the release rate constant of CS was 0.36 %(ppm/ppm) min(-1).
引用
收藏
页码:226 / 231
页数:6
相关论文
共 6 条
  • [1] Analysis of Dissolution of Salicylamide from Carrageenan Based Hard-Shell Capsules: A Study of the Drug-Matrix Interaction
    Fauzi, Muhammad Al Rizqi Dharma
    Hendradi, Esti
    Pudjiastuti, Pratiwi
    Widodo, Riyanto Teguh
    [J]. INDONESIAN JOURNAL OF CHEMISTRY, 2021, 21 (01) : 148 - 156
  • [2] Characterization, Disintegration, and Dissolution Analyses of Carrageenan-Based Hard-Shell Capsules Cross-Linked with Maltodextrin as a Potential Alternative Drug Delivery System
    Fauzi, Muhammad Al Rizqi Dharma
    Pudjiastuti, Pratiwi
    Hendradi, Esti
    Widodo, Riyanto Teguh
    Amin, Mohd. Cairul Iqbal Mohd.
    [J]. INTERNATIONAL JOURNAL OF POLYMER SCIENCE, 2020, 2020
  • [3] First Order Kinetics of Salicylamide Release from κ-Carrageenan Hard Shell Capsules in Comparison with Gelatin
    Pudjiastuti, P.
    Hendradi, E.
    Wafiroh, S.
    Darmokoesoemo, H.
    Fauzi, M. A. R. D.
    Nahar, L.
    Sarker, S. D.
    [J]. 12TH CONGRESS OF INDONESIAN SOC. FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY IN CONJUNCTION WITH THE 2ND INT. CONF COLLABORATION SEMINAR OF CHEMISTRY AND INDUSTRY (COSCI) AND ANMICRO WORKSHOP, 2018, 2019, 217
  • [4] Cross-linking of hard gelatin carbamazepine capsules: effect of dissolution conditions on in vitro drug release
    Marchais, H
    Cayzeele, G
    Legendre, JY
    Skiba, M
    Arnaud, P
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2003, 19 (2-3) : 129 - 132
  • [5] Comparison of the release profiles of a water soluble drug carried by Eudragit-coated capsules in different in-vitro dissolution liquids
    Chan, WA
    Boswell, CD
    Zhang, Z
    [J]. POWDER TECHNOLOGY, 2001, 119 (01) : 26 - 32
  • [6] In Vitro-In Vivo Correlation in Cocrystal Dissolution: Consideration of Drug Release Profiles Based on Coformer Dissolution and Absorption Behavior
    Kataoka, Makoto
    Minami, Keiko
    Takagi, Toshihide
    Amidon, Gregory E.
    Yamashita, Shinji
    [J]. MOLECULAR PHARMACEUTICS, 2021, 18 (11) : 4122 - 4130